Home › Funds › Nan Fung Group Holdings Ltd › EVMN
Nan Fung Group Holdings Ltd position in EVMN
EVOMMUNE INC · Health Care
Nan Fung Group Holdings Ltd reported holding 1,441,032 shares of EVMN (EVOMMUNE INC) in its Q3 2026 13F filing — a position valued at US$11.9M, representing 8.04% of its reported portfolio and ranking #5 among its reported holdings. Nan Fung Group Holdings Ltd has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Nan Fung Group Holdings Ltd's EVMN position evolved
Nan Fung Group Holdings Ltd first disclosed a stake in EVMN in Q4 2025 at 1,441,032 shares (US$24.7M). The position peaked in Q1 2026 at 1,441,032 shares, worth US$33.1M. Across 4 filings, Nan Fung Group Holdings Ltd held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,441,032 shares valued at US$11.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.44M | $24.67M | New |
| Q1 2026 | 1.44M | $33.13M | Hold |
| Q2 2026 | 1.44M | $19.15M | Hold |
| Q3 2026 | 1.44M | $11.90M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EVMN and 13F data
EVMN (EVOMMUNE INC) is a Health Care company. 105 other funds we track also report a position in EVMN — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$46.4M), EQT Fund Management S.a r.l. (US$43.7M), SymBiosis Capital Partners, LLC (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EVMN
- RA CAPITAL MANAGEMENT, L.P. 3.49M sh · $46.44M · Q2 2026
- EQT Fund Management S.a r.l. 5.29M sh · $43.68M · Q3 2026
- SymBiosis Capital Partners, LLC 1.28M sh · $29.45M · Q1 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M sh · $15.92M · Q3 2026
- Defilade Capital Management, L.P. 793.14K sh · $10.54M · Q2 2026
- Velan Capital Investment Management LP 451.25K sh · $6.00M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 594.03K sh · $4.91M · Q3 2026
- GREAT POINT PARTNERS LLC 325.00K sh · $4.32M · Q2 2026
- Avidity Partners Management LP 75.00K sh · $996.75K · Q2 2026
- NEXTBio Capital Management LP 119.06K sh · $983.46K · Q3 2026
- Andera Partners 97.36K sh · $804.21K · Q3 2026
More on Nan Fung Group Holdings Ltd
FAQ
How long has Nan Fung Group Holdings Ltd held EVMN?
Nan Fung Group Holdings Ltd has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Nan Fung Group Holdings Ltd's current position in EVMN?
As of Q3 2026, Nan Fung Group Holdings Ltd holds 1.44M shares of EVMN (EVOMMUNE INC), valued at $11.90M, representing 8.04% of its reported portfolio and ranking #5.
Has Nan Fung Group Holdings Ltd been buying or selling EVMN?
In the latest 13F filing (Q3 2026), Nan Fung Group Holdings Ltd held unchanged its position in EVMN. The position peaked in Q1 2026 at 1.44M shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include RA CAPITAL MANAGEMENT, L.P., EQT Fund Management S.a r.l., SymBiosis Capital Partners, LLC, among 105 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.